• Home
  • Ruxolitinib 25mg
  • Ruxolitinib 25mg

Ruxolitinib 25mg

52078

Ruxolitinib is used for myelofibrosis, a bone marrow disease that can cause an enlarged spleen, low blood counts, and symptoms such as fatigue or night sweats.

It is also used for polycythaemia vera after hydroxyurea has not worked well enough or is not tolerated, and for some forms of graft-versus-host disease.

Usual dose range: 5mg to 25mg twice daily, with the starting dose based mainly on platelet count, blood counts, and the condition being treated.

Indications vary by country and change over time; this website contains information for general patient information and should be checked against local prescribing information before clinical use.

Verification Approach: Each indication and usual dose-range sentence was drafted from at least two recognised medicines information sources, usually FDA/DailyMed or an FDA label plus EMA/eMC, MedlinePlus, Mayo Clinic, Cancer Research UK, NCI/ Cancer.gov, or another reputable medicines-information source. Doses are general adult/patient-information ranges and must not be used to prescribe or change treatment.
  • FDA/DailyMed prescribing information and FDA Oncology/Hematology approval notifications.
  • EMA and UK eMC Summary of Product
    Characteristics and patient leaflets where available.
  • NCI Cancer Drug Information/Cancer.gov and Cancer Research UK medicine information where available.
  • MedlinePlus, NHS/NICE, and other national medicines information for non-oncology or immune/respiratory medicines.
  • Peer-reviewed FDA approval summaries or manufacturer regulatory notices for very new, withdrawn, or region-specific
    indications.